ZA200504415B - Malaria vaccine - Google Patents
Malaria vaccine Download PDFInfo
- Publication number
- ZA200504415B ZA200504415B ZA200504415A ZA200504415A ZA200504415B ZA 200504415 B ZA200504415 B ZA 200504415B ZA 200504415 A ZA200504415 A ZA 200504415A ZA 200504415 A ZA200504415 A ZA 200504415A ZA 200504415 B ZA200504415 B ZA 200504415B
- Authority
- ZA
- South Africa
- Prior art keywords
- protein
- glurp
- msp3
- vaccine
- falciparum
- Prior art date
Links
- 229940124735 malaria vaccine Drugs 0.000 title description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 70
- 229960005486 vaccine Drugs 0.000 claims abstract description 67
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 63
- 201000004792 malaria Diseases 0.000 claims abstract description 41
- 241000223960 Plasmodium falciparum Species 0.000 claims abstract description 35
- 239000000203 mixture Substances 0.000 claims abstract description 35
- 210000003936 merozoite Anatomy 0.000 claims abstract description 13
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 12
- 229930195712 glutamate Natural products 0.000 claims abstract description 11
- 241000224016 Plasmodium Species 0.000 claims abstract description 10
- 239000000427 antigen Substances 0.000 claims description 47
- 108091007433 antigens Proteins 0.000 claims description 47
- 102000036639 antigens Human genes 0.000 claims description 47
- 108020001507 fusion proteins Proteins 0.000 claims description 37
- 102000037865 fusion proteins Human genes 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 21
- 230000002163 immunogen Effects 0.000 claims description 19
- 239000012634 fragment Substances 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 13
- 230000004927 fusion Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- -1 MSP3 Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 101100024442 Anaplasma marginale msp4 gene Proteins 0.000 claims description 7
- 101100373502 Enterobacteria phage T4 y06P gene Proteins 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 101100373500 Enterobacteria phage T4 y06N gene Proteins 0.000 claims description 5
- 101000895911 Plasmodium falciparum (isolate Camp / Malaysia) Erythrocyte-binding antigen 175 Proteins 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 5
- 108010057081 Merozoite Surface Protein 1 Proteins 0.000 claims description 4
- 101100203666 Mus musculus Spag6 gene Proteins 0.000 claims description 4
- 101100373501 Enterobacteria phage T4 y06O gene Proteins 0.000 claims description 3
- 102100022851 Rab5 GDP/GTP exchange factor Human genes 0.000 claims description 2
- 101710203837 Replication-associated protein Proteins 0.000 claims description 2
- 102100032467 Transmembrane protease serine 13 Human genes 0.000 claims 6
- 230000002265 prevention Effects 0.000 claims 4
- 101710086591 Hepatocyte growth factor-like protein Proteins 0.000 claims 3
- 101000798707 Homo sapiens Transmembrane protease serine 13 Proteins 0.000 claims 3
- 101000967612 Onchocerca volvulus Major sperm protein 2 Proteins 0.000 claims 3
- 101710201137 Photosystem II manganese-stabilizing polypeptide Proteins 0.000 claims 3
- 101001055956 Homo sapiens Mannan-binding lectin serine protease 1 Proteins 0.000 claims 1
- 241000178948 Lactococcus sp. Species 0.000 claims 1
- 102100026061 Mannan-binding lectin serine protease 1 Human genes 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 238000000765 microspectrophotometry Methods 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- 101150089906 resA gene Proteins 0.000 claims 1
- 241000194035 Lactococcus lactis Species 0.000 abstract description 22
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract description 16
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract description 16
- 230000005875 antibody response Effects 0.000 abstract description 10
- 235000014897 Streptococcus lactis Nutrition 0.000 abstract description 9
- 238000002474 experimental method Methods 0.000 abstract description 9
- 108010052285 Membrane Proteins Proteins 0.000 abstract description 6
- 102000018697 Membrane Proteins Human genes 0.000 abstract description 6
- 238000002649 immunization Methods 0.000 abstract description 5
- 230000003053 immunization Effects 0.000 abstract description 5
- 108020001775 protein parts Proteins 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 41
- 102000004196 processed proteins & peptides Human genes 0.000 description 36
- 244000045947 parasite Species 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 25
- 229920001184 polypeptide Polymers 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 19
- 230000004044 response Effects 0.000 description 19
- 210000002381 plasma Anatomy 0.000 description 16
- 238000002965 ELISA Methods 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 239000013612 plasmid Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 230000036039 immunity Effects 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 230000028993 immune response Effects 0.000 description 11
- 239000002773 nucleotide Substances 0.000 description 11
- 125000003729 nucleotide group Chemical group 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 210000003719 b-lymphocyte Anatomy 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 229940024606 amino acid Drugs 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 8
- 102000004127 Cytokines Human genes 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 8
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 230000003229 cytophilic effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 229940049906 glutamate Drugs 0.000 description 6
- 229940090044 injection Drugs 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 206010035500 Plasmodium falciparum infection Diseases 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000010276 construction Methods 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 208000002476 Falciparum Malaria Diseases 0.000 description 4
- 201000011336 Plasmodium falciparum malaria Diseases 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 230000036755 cellular response Effects 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000009545 invasion Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000013207 serial dilution Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 241000282693 Cercopithecidae Species 0.000 description 3
- 108010041986 DNA Vaccines Proteins 0.000 description 3
- 229940021995 DNA vaccine Drugs 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 241000194036 Lactococcus Species 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 241000223808 Plasmodium reichenowi Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000003698 anagen phase Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000005304 joining Methods 0.000 description 3
- 238000013507 mapping Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 201000008827 tuberculosis Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108091036414 Polyinosinic:polycytidylic acid Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000000240 adjuvant effect Effects 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 108091036078 conserved sequence Proteins 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 101150079015 esxB gene Proteins 0.000 description 2
- 101150069551 esxH gene Proteins 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000005745 host immune response Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940115272 polyinosinic:polycytidylic acid Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000004007 reversed phase HPLC Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- WLNBMPZUVDTASE-HXIISURNSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO.O=C[C@H]([NH3+])[C@@H](O)[C@H](O)[C@H](O)CO WLNBMPZUVDTASE-HXIISURNSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QGNCLSQOOODALH-UHFFFAOYSA-N 2-cyano-3-hydroxy-3-phenylprop-2-enoic acid Chemical compound OC(=O)C(C#N)=C(O)C1=CC=CC=C1 QGNCLSQOOODALH-UHFFFAOYSA-N 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- IMCUVBSHZXQITN-UHFFFAOYSA-N 4-[[4-(4-chlorophenyl)-5-(2-methoxy-2-oxoethyl)-1,3-thiazol-2-yl]amino]-4-oxobutanoic acid Chemical compound S1C(NC(=O)CCC(O)=O)=NC(C=2C=CC(Cl)=CC=2)=C1CC(=O)OC IMCUVBSHZXQITN-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 108091092742 A-DNA Proteins 0.000 description 1
- 108010075348 Activated-Leukocyte Cell Adhesion Molecule Proteins 0.000 description 1
- 239000012099 Alexa Fluor family Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710203310 Apical membrane antigen 1 Proteins 0.000 description 1
- 101150078806 BCAT2 gene Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100026413 Branched-chain-amino-acid aminotransferase, mitochondrial Human genes 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 101100440271 Caenorhabditis elegans ccf-1 gene Proteins 0.000 description 1
- 101100024439 Caenorhabditis elegans msp-3 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000736839 Chara Species 0.000 description 1
- 241000581444 Clinidae Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000037164 Collema parvum Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 101710088334 Diacylglycerol acyltransferase/mycolyltransferase Ag85B Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 101150099000 EXPA1 gene Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001302160 Escherichia coli str. K-12 substr. DH10B Species 0.000 description 1
- 102100029095 Exportin-1 Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 108010073807 IgG Receptors Proteins 0.000 description 1
- 102000009490 IgG Receptors Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 238000012313 Kruskal-Wallis test Methods 0.000 description 1
- 125000002059 L-arginyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C([H])([H])N([H])C(=N[H])N([H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101100026709 Mus musculus Nprl3 gene Proteins 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 102000011830 Neural cell adhesion Human genes 0.000 description 1
- 108050002172 Neural cell adhesion Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 208000009182 Parasitemia Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000237988 Patellidae Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 101800004193 Peptide P3 Proteins 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- 241000223801 Plasmodium knowlesi Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710132632 Protein C4 Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 238000011579 SCID mouse model Methods 0.000 description 1
- 101100119348 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) EXP1 gene Proteins 0.000 description 1
- 241000282696 Saimiri sciureus Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 102100037253 Solute carrier family 45 member 3 Human genes 0.000 description 1
- 101100269618 Streptococcus pneumoniae serotype 4 (strain ATCC BAA-334 / TIGR4) aliA gene Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241000512294 Thais Species 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108010005233 alanylglutamic acid Proteins 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 229960000190 bacillus calmette–guérin vaccine Drugs 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 108700002148 exportin 1 Proteins 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 101150045500 galK gene Proteins 0.000 description 1
- 101150041954 galU gene Proteins 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 235000021474 generally recognized As safe (food) Nutrition 0.000 description 1
- 235000021473 generally recognized as safe (food ingredients) Nutrition 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 101150096208 gtaB gene Proteins 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 108010079891 prostein Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229940070741 purified protein derivative of tuberculin Drugs 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 101150098466 rpsL gene Proteins 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 210000001563 schizont Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000037369 susceptibility to malaria Diseases 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200201741A DK200201741A (da) | 2002-11-12 | 2002-11-12 | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
| DKPA200301307 | 2003-09-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200504415B true ZA200504415B (en) | 2006-03-29 |
Family
ID=32313776
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200504415A ZA200504415B (en) | 2002-11-12 | 2006-01-17 | Malaria vaccine |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7749507B2 (fr) |
| EP (1) | EP1567189B1 (fr) |
| JP (1) | JP4573773B2 (fr) |
| CN (1) | CN1741815B (fr) |
| AT (1) | ATE432081T1 (fr) |
| AU (1) | AU2003275949B2 (fr) |
| BR (1) | BR0315205A (fr) |
| CA (1) | CA2505724C (fr) |
| DE (1) | DE60327801D1 (fr) |
| DK (2) | DK200201741A (fr) |
| ES (1) | ES2326415T3 (fr) |
| HK (1) | HK1080754A1 (fr) |
| WO (1) | WO2004043488A1 (fr) |
| ZA (1) | ZA200504415B (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2697022B1 (fr) * | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
| US20030161840A1 (en) * | 1992-10-19 | 2003-08-28 | Institut Pasteur | Plasmodium falciparum antigens inducing protective antibodies |
| DK200201741A (da) * | 2002-11-12 | 2003-09-16 | Statens Seruminstitut | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
| US20050112133A1 (en) * | 2003-10-24 | 2005-05-26 | Pierre Druilhe | GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it |
| US7488489B2 (en) * | 2004-08-03 | 2009-02-10 | Institut Pasteur | Identification of a conserved region of Plasmodium falciparum MSP3 targeted by biologically active antibodies |
| MX2011011676A (es) * | 2009-05-05 | 2012-04-02 | Cadila Healthcare Ltd | Vacuna combinada sarampion-paludismo. |
| EP2454268B1 (fr) | 2009-07-15 | 2014-09-10 | The University Of British Columbia | Glycosides 2,3-fluorés en tant qu'inhibiteurs de neuraminidase et leur utilisation en tant qu'agents antiviraux |
| EP2385107B1 (fr) | 2010-05-03 | 2016-08-24 | Institut Pasteur | Composés immunologiques basés sur un vecteur de lentivirus contre le paludisme |
| EP2763694B1 (fr) * | 2011-10-04 | 2018-01-03 | Statens Serum Institut | Production d'une protéine riche en cystéine |
| US20140348870A1 (en) * | 2011-11-30 | 2014-11-27 | The Regents Of The University Of California | Immunogenic plasmodium falciparum antigen compositions and uses thereof |
| CN102533677B (zh) * | 2012-01-10 | 2013-07-24 | 特菲(天津)生物医药科技有限公司 | 一种疟疾疫苗及其制备方法 |
| CN107954963A (zh) | 2012-01-19 | 2018-04-24 | 不列颠哥伦比亚大学 | 3’平伏氟取代的神经氨酸酶抑制剂化合物、组合物及其用作抗病毒剂的方法 |
| CN105628928A (zh) * | 2014-11-11 | 2016-06-01 | 深圳国际旅行卫生保健中心 | 可用于辅助诊断疟疾的试剂盒 |
| CN105652009B (zh) * | 2014-11-11 | 2018-04-24 | 中国科学院苏州纳米技术与纳米仿生研究所 | 可用于辅助诊断疟疾的试剂盒 |
| EP3487526B1 (fr) * | 2016-07-21 | 2022-07-06 | VAC4all Pte. Ltd. | Protéines de biofusion comme vaccins antipaludiques |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK519188D0 (da) * | 1988-09-16 | 1988-09-16 | Statens Seruminstitut | Kemisk forbindelse |
| US5231168A (en) * | 1988-09-16 | 1993-07-27 | Statens Seruminstitut | Malaria antigen |
| AU645482B2 (en) * | 1988-09-16 | 1994-01-20 | Statens Serum Institut | A malaria antigen |
| FR2697022B1 (fr) * | 1992-10-19 | 1994-12-16 | Pasteur Institut | Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination. |
| JP2002537354A (ja) * | 1999-02-25 | 2002-11-05 | スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム | ペプチド、及びＨ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ由来の担体を含む免疫原 |
| WO2002092628A2 (fr) * | 2001-05-16 | 2002-11-21 | Institut Pasteur | Antigenes de plasmodium falciparum et leurs applications vaccinales et diagnostiques |
| DK200201741A (da) * | 2002-11-12 | 2003-09-16 | Statens Seruminstitut | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
-
2002
- 2002-11-12 DK DK200201741A patent/DK200201741A/da not_active Application Discontinuation
-
2003
- 2003-11-06 ES ES03810941T patent/ES2326415T3/es not_active Expired - Lifetime
- 2003-11-06 CN CN2003801031543A patent/CN1741815B/zh not_active Expired - Lifetime
- 2003-11-06 EP EP03810941A patent/EP1567189B1/fr not_active Expired - Lifetime
- 2003-11-06 CA CA2505724A patent/CA2505724C/fr not_active Expired - Lifetime
- 2003-11-06 AT AT03810941T patent/ATE432081T1/de not_active IP Right Cessation
- 2003-11-06 WO PCT/DK2003/000759 patent/WO2004043488A1/fr active Application Filing
- 2003-11-06 DE DE60327801T patent/DE60327801D1/de not_active Expired - Lifetime
- 2003-11-06 AU AU2003275949A patent/AU2003275949B2/en not_active Expired
- 2003-11-06 JP JP2005506641A patent/JP4573773B2/ja not_active Expired - Fee Related
- 2003-11-06 BR BR0315205-7A patent/BR0315205A/pt not_active IP Right Cessation
- 2003-11-06 DK DK03810941T patent/DK1567189T3/da active
-
2005
- 2005-05-12 US US11/128,660 patent/US7749507B2/en active Active
-
2006
- 2006-01-17 ZA ZA200504415A patent/ZA200504415B/en unknown
- 2006-02-27 HK HK06102595.9A patent/HK1080754A1/xx not_active IP Right Cessation
-
2010
- 2010-06-03 US US12/793,575 patent/US20110020387A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DK1567189T3 (da) | 2009-09-14 |
| CN1741815A (zh) | 2006-03-01 |
| EP1567189A1 (fr) | 2005-08-31 |
| CN1741815B (zh) | 2010-05-26 |
| ATE432081T1 (de) | 2009-06-15 |
| ES2326415T3 (es) | 2009-10-09 |
| WO2004043488A1 (fr) | 2004-05-27 |
| CA2505724A1 (fr) | 2004-05-27 |
| AU2003275949A1 (en) | 2004-06-03 |
| CA2505724C (fr) | 2015-06-30 |
| BR0315205A (pt) | 2005-08-16 |
| DK200201741A (da) | 2003-09-16 |
| JP4573773B2 (ja) | 2010-11-04 |
| US20110020387A1 (en) | 2011-01-27 |
| EP1567189B1 (fr) | 2009-05-27 |
| JP2006512926A (ja) | 2006-04-20 |
| HK1080754A1 (en) | 2006-05-04 |
| US20060024324A1 (en) | 2006-02-02 |
| US7749507B2 (en) | 2010-07-06 |
| AU2003275949B2 (en) | 2008-06-05 |
| DE60327801D1 (de) | 2009-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200504415B (en) | Malaria vaccine | |
| US7211256B2 (en) | Plasmodium falciparum antigens inducing protective antibodies | |
| US20070003562A1 (en) | GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it | |
| PL186774B1 (pl) | Związki i sposoby do immunoterapii i diagnostyki gruźlicy | |
| US5231168A (en) | Malaria antigen | |
| CA2462946C (fr) | Vaccin a base de proteine 142 de merozoite p.falciparum de recom binaison | |
| AU2011326338A1 (en) | Treatment and prevention of malaria | |
| US20070098738A1 (en) | MSP-3-like family of genes | |
| JP2000506381A (ja) | マラリア原虫ｍｓｐ―１のｃ末端断片を含む組換えタンパク質 | |
| US5116755A (en) | Asexual blood stage antigens of plasmodium falciparum which encode a rhoptry protein | |
| US20050075496A1 (en) | Plasmodium falciparum antigens and their vaccine and diagnostic applications | |
| US7306806B2 (en) | Recombinant P. falciparum merozoite protein-142 vaccine | |
| US8298546B2 (en) | Isolation and purification of P. falciparum merozoite protein-142 vaccine | |
| PT97117A (pt) | Processo para a preparacao de derivados polipeptidicos e de composicoes imunogenicas que os contem | |
| Coppel | Asexual blood stage antigens of Plasmodium falciparum which encode a rhoptry protein | |
| JPS62502444A (ja) | プラズモジウム・ファルシパルムの高い反復性を有する抗原 |